From GlobeNewswire: 2025-06-02 08:00:00

Nutriband Inc. reported a record first-quarter revenue of $667,000USD, up 63% YOY. The company is expanding its kinesiology tape output and rolling out products in major retail locations like Target and Walmart. Nutriband also formalized a partnership with Kindeva Drug Delivery for the development of AVERSA Fentanyl, an abuse-deterrent opioid patch with potential peak annual US sales of $80 million to $200 million.

AVERSA Fentanyl is designed to deter abuse and misuse of transdermal fentanyl patches. Nutriband’s portfolio includes transdermal pharmaceutical products, with a focus on abuse-deterrent technology. The company’s forward-looking statements highlight risks and uncertainties in product development, patent protection, regulatory approval, and market conditions. For more information, contact Nutriband Inc. at 407-377-6695 or [email protected].



Read more at GlobeNewswire:: Nutriband Inc. Quarterly Report Highlights Record Revenue